Expert Review of Clinical Pharmacology最新文献

Sparsentan: a dual endothelin and angiotensin II receptor antagonist approved for IgA nephropathy. Sparsentan：批准用于IgA肾病的双重内皮素和血管紧张素II受体拮抗剂。

IF 3.6 3区医学

Expert Review of Clinical Pharmacology Pub Date : 2025-07-16 DOI: 10.1080/17512433.2025.2532659

Gates B Colbert, Hector M Madariaga, Anna Gaddy, Mohamed E Elrggal, Edgar V Lerma

{"title":"Sparsentan: a dual endothelin and angiotensin II receptor antagonist approved for IgA nephropathy.","authors":"Gates B Colbert, Hector M Madariaga, Anna Gaddy, Mohamed E Elrggal, Edgar V Lerma","doi":"10.1080/17512433.2025.2532659","DOIUrl":"10.1080/17512433.2025.2532659","url":null,"abstract":"Introduction: IgA nephropathy (IgAN) is the most common primary glomerulonephritis. For decades, the only medication treatments that were widely accepted were the use of renin-angiotensin aldosterone inhibitors and corticosteroids. The early 2020s have brought a flurry of new treatments to the once dark IgA treatment landscape. Sparsentan is a novel dual-endothelin angiotensin receptor antagonist that has been approved as an add-on therapy for the treatment of IgAN.Areas covered: We discuss the treatment landscape and the unmet needs for treating IgA nephropathy. Multiple clinical trials showing the efficacy of sparsentan including DUET, PROTECT, SPARTACUS, and SPARTAN will be described. Additionally, we will preview the future options for IgA patients.Expert opinion: Sparsentan is a major step forward in improving outcomes for patients with IgAN. This once-a-day agent, in addition to other standards of care, limits proteinuria and progression to ESKD and kidney transplantation. The ability to lower proteinuria without weakening the immune system is a substantial gain for patients. As an agent that impacts the glomeruli directly, sparsentan is able to limit damage in mechanisms that previous RASi and steroids have not. Including sparsentan in the combination treatment for IgAN must be considered for adequate kidney protection.","PeriodicalId":12207,"journal":{"name":"Expert Review of Clinical Pharmacology","volume":" ","pages":"1-8"},"PeriodicalIF":3.6,"publicationDate":"2025-07-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144599801","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A pharmacological profile of triheptanoin for the treatment of long-chain fatty acid oxidation disorders. 三庚酸治疗长链脂肪酸氧化障碍的药理学概况。

IF 3.6 3区医学

Expert Review of Clinical Pharmacology Pub Date : 2025-07-15 DOI: 10.1080/17512433.2025.2528835

Raelynn Forsyth, Jerry Vockley

{"title":"A pharmacological profile of triheptanoin for the treatment of long-chain fatty acid oxidation disorders.","authors":"Raelynn Forsyth, Jerry Vockley","doi":"10.1080/17512433.2025.2528835","DOIUrl":"10.1080/17512433.2025.2528835","url":null,"abstract":"Introduction: Long-chain fatty acid oxidation disorders (LC-FAODs) are rare inherited metabolic defects that present across the lifespan with skeletal, cardiac, and hepatic complications due to deficiency of energy production. Historically, medium-chain triglycerides (MCT) were used in their management of LC-FAODs, but individuals still developed symptoms due to depletion of tricarboxylic acid (TCA) cycle substrates.Areas covered: This review covers the pathophysiology of LC-FAODs, highlighting the rationale for the use of triheptanoin (Dojolvi®), an MCT consisting of three 7-carbon fatty acids, in the nutritional management of LC-FAODs.Expert opinion: Triheptanoin is an anaplerotic source of calories for treatment of LC-FAODs, providing a source of substrates to sustain the TCA cycle, gluconeogenesis, and energy production. Use of triheptanoin prior to its regulatory approval demonstrated significant clinical benefit. Clinical benefit was thereafter demonstrated in clinical trials, with a positive cardiac effect in a double-blinded, randomized controlled comparison to MCT, and improvement in major clinical events in open-label extension studies. Side effects of triheptanoin are primarily GI intolerance similar to conventional MCT oil. Use prior to onset of symptoms in severe disease is recommended. Its use is not limited to LC-FAODs with active studies looking at its potential benefit in other conditions.","PeriodicalId":12207,"journal":{"name":"Expert Review of Clinical Pharmacology","volume":" ","pages":"1-12"},"PeriodicalIF":3.6,"publicationDate":"2025-07-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144599800","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Clinical pharmacologic considerations for antibody drug conjugates in gynecologic cancers. 抗体药物偶联物在妇科癌症中的临床药理学考虑。

IF 3.6 3区医学

Expert Review of Clinical Pharmacology Pub Date : 2025-07-14 DOI: 10.1080/17512433.2025.2535178

Victoria M Ettorre, Luca Palmieri, Alessandro D Santin

{"title":"Clinical pharmacologic considerations for antibody drug conjugates in gynecologic cancers.","authors":"Victoria M Ettorre, Luca Palmieri, Alessandro D Santin","doi":"10.1080/17512433.2025.2535178","DOIUrl":"https://doi.org/10.1080/17512433.2025.2535178","url":null,"abstract":"Introduction: The mainstay of treatment for gynecologic cancers includes surgical debulking followed in a subset of patients by chemotherapy, radiation, hormonal therapy and immunotherapy. In the last 10 years, antibody - drug conjugates (ADCs) have provided new therapeutic options and significant promise for the treatment of patients with recurrent gynecologic tumors.Areas covered: Information for this review article was obtained by literature review on PUBMED using phrases such as 'antibody drug conjugates in gynecologic cancers,' 'FDA approval for antibody drug conjugates in gynecologic cancers,' 'tisotumab vedotin,' 'mirvetuximab soravtansine,' 'trastuzumab deruxitcan,' 'sacituzumab govitecan,' 'datopotomab deruxtecan,' and 'sacituzumab tirumotecan.'Expert opinion: ADCs represent a new frontier for the treatment of gynecologic malignancies. The few ADCs currently approved by the FDA for the treatment of gynecologic cancers demonstrated higher clinical activity and better tolerability when compared to standard investigator choice chemotherapy. Streamlined pathologic tissue testing of tumor samples is required for widespread use of ADCs, and future prospective studies are needed to ascertain whether ADCs can be introduced in first-line treatment for patients with advanced gynecologic malignancies.","PeriodicalId":12207,"journal":{"name":"Expert Review of Clinical Pharmacology","volume":" ","pages":""},"PeriodicalIF":3.6,"publicationDate":"2025-07-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144636643","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Anti-seizure medications in patients with renal failure undergoing dialysis: how to manage? 透析肾衰患者的抗癫痫药物：如何管理？

IF 3.6 3区医学

Expert Review of Clinical Pharmacology Pub Date : 2025-07-09 DOI: 10.1080/17512433.2025.2531109

Oreste Marsico, Angelo Pascarella, Roberta Cutellè, Roberto Di Iorio, Alessandro Bulgari, Domenico Abelardo, Sara Gasparini, Vittoria Cianci, Davide Bolignano, Emilio Russo, Roberta Roberti, Carmen De Caro, Eleonora Rosati, Simona Lattanzi, Umberto Aguglia, Edoardo Ferlazzo

{"title":"Anti-seizure medications in patients with renal failure undergoing dialysis: how to manage?","authors":"Oreste Marsico, Angelo Pascarella, Roberta Cutellè, Roberto Di Iorio, Alessandro Bulgari, Domenico Abelardo, Sara Gasparini, Vittoria Cianci, Davide Bolignano, Emilio Russo, Roberta Roberti, Carmen De Caro, Eleonora Rosati, Simona Lattanzi, Umberto Aguglia, Edoardo Ferlazzo","doi":"10.1080/17512433.2025.2531109","DOIUrl":"10.1080/17512433.2025.2531109","url":null,"abstract":"Introduction: Managing epilepsy in patients with end-stage kidney disease presents unique challenges due to altered pharmacokinetics of anti-seizure medications (ASMs) and the effects of dialysis treatments. Dialysis can significantly affect ASM clearance, requiring careful dosing adjustments to maintain therapeutic efficacy while avoiding toxicity. This review aims to provide an up-to-date overview of the current knowledge and to offer practical clinical guidance on the use of ASMs in patients undergoing hemodialysis and peritoneal dialysis.Areas covered: Relevant literature on ASMs in dialysis patients was searched in MEDLINE and Google Scholar. Additional information was retrieved from the summary of product characteristics for each ASM.Expert opinion: Evidence on the management of ASMs in patients receiving dialysis is still limited, mainly based on small observational studies and case reports. Currently, no official guidelines are available. Effective treatment strategies require individualized approaches. ASMs with low protein binding and predominant renal elimination generally require post-dialysis dose adjustments. Therapeutic drug monitoring may be indicated in some cases. Data regarding the impact of different dialysis filter types on ASM clearance are sparse. The paucity of data, especially for newer ASMs, underscores the urgent need for further research to establish comprehensive, evidence-based recommendations for this vulnerable patient population.","PeriodicalId":12207,"journal":{"name":"Expert Review of Clinical Pharmacology","volume":" ","pages":"1-13"},"PeriodicalIF":3.6,"publicationDate":"2025-07-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144567356","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Hormonal contraception, past, present, and future part 2: optimizing combined oral contraceptives to decrease risks for healthy women. 激素避孕，过去、现在和未来：优化口服避孕药组合以降低健康妇女的风险。

IF 3.6 3区医学

Expert Review of Clinical Pharmacology Pub Date : 2025-06-01 Epub Date: 2025-06-14 DOI: 10.1080/17512433.2025.2517747

Manuela Farris, Carlo Bastianelli, Marwan Habiba, Giuseppe Benagiano

{"title":"Hormonal contraception, past, present, and future part 2: optimizing combined oral contraceptives to decrease risks for healthy women.","authors":"Manuela Farris, Carlo Bastianelli, Marwan Habiba, Giuseppe Benagiano","doi":"10.1080/17512433.2025.2517747","DOIUrl":"10.1080/17512433.2025.2517747","url":null,"abstract":"Introduction: Pincus and his group's initial research on hormonal contraception focused on progesterone. However, the natural compound could not be utilized in clinical practice because of the high incidence of breakthrough bleeding and its low oral availability. This led to the introduction of orally active progestins. The estrogen was added to ensure proper cycle control.Areas covered: Concern about side effects of combined oral contraceptive pills (COC) and specifically the increased occurrence of thromboembolism was raised at the very early stages of clinical use. These were attributed to the estrogenic component, ethinyl estradiol (EE). The first pill scare followed the publication in 1977 of evidence of thromboembolism-related mortality in COC users. This and subsequent alarming publications acted as the engine for a successful attempt to substantially decrease the daily content of EE in a COC. Over time, adverse events were also reported for the newer progestins compared to levonorgestrel.Expert opinion: Attempts have been made to utilize natural estrogens in COC based on the assumption that this will reduce adverse effects. The wide range of progestins available for use in COC renders comparisons between preparations more challenging. Each progestin has its own androgenic, antiandrogenic, antiestrogenic, and mineralocorticoid activity and, consequently, a unique risk and benefit profile.","PeriodicalId":12207,"journal":{"name":"Expert Review of Clinical Pharmacology","volume":" ","pages":"361-372"},"PeriodicalIF":3.6,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144257693","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Precision dosing of perampanel in pediatric patients receiving oxcarbazepine combination therapy: physiologically based pharmacokinetic modeling and simulation. 在接受奥卡西平联合治疗的儿科患者中精确给药perampanel：基于生理的药代动力学建模和模拟。

IF 3.6 3区医学

Expert Review of Clinical Pharmacology Pub Date : 2025-06-01 Epub Date: 2025-07-04 DOI: 10.1080/17512433.2025.2527079

Si-Ting Liu, Cheng-Jie Ke, Jing Su, Yu-Die Qian, Wan-Hong Wu, Xi Lin, Wei-Wei Lin

{"title":"Precision dosing of perampanel in pediatric patients receiving oxcarbazepine combination therapy: physiologically based pharmacokinetic modeling and simulation.","authors":"Si-Ting Liu, Cheng-Jie Ke, Jing Su, Yu-Die Qian, Wan-Hong Wu, Xi Lin, Wei-Wei Lin","doi":"10.1080/17512433.2025.2527079","DOIUrl":"10.1080/17512433.2025.2527079","url":null,"abstract":"Background: The combination of oxcarbazepine (OXC) with perampanel (PER) considerably reduces the blood concentration of PER in children, decreasing the antiepileptic effect of PER. This study aimed to predict PER exposure and provide recommendations for dose adjustment in pediatric patients.Research design and methods: Physiologically based pharmacokinetic (PBPK) models of PER and OXC for adults and pediatrics were developed and verified, followed by drug - drug interaction (DDI) modeling and validation of the models against available pharmacokinetic data.Results: The simulated results of the PBPK models exhibited a fold-error value between 0.5 and 2, indicating good predictive abilities; the DDI model results supported the observational results. Based on the prediction results, the recommended dosages of PER for 4-10- and 10-14-year-old children are 2-6 and 4-8 mg q.n., respectively. Additionally, the recommended doses of PER in PER with OXC combination therapy for children aged 4-10 and 10-14 years are 6-12 and 10-12 mg q.n., respectively.Conclusion: The PBPK and DDI models of PER were successfully established, which serve as references for the rational use of this medication in children.","PeriodicalId":12207,"journal":{"name":"Expert Review of Clinical Pharmacology","volume":" ","pages":"425-436"},"PeriodicalIF":3.6,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144552743","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Hormonal contraception, past, present, and future part 1: the early path - facts, stories, and controversies. 激素避孕，过去，现在和未来第一部分：早期路径-事实，故事和争议。

IF 3.6 3区医学

Expert Review of Clinical Pharmacology Pub Date : 2025-06-01 Epub Date: 2025-06-15 DOI: 10.1080/17512433.2025.2517748

Manuela Farris, Carlo Bastianelli, Marwan Habiba, Giuseppe Benagiano

{"title":"Hormonal contraception, past, present, and future part 1: the early path - facts, stories, and controversies.","authors":"Manuela Farris, Carlo Bastianelli, Marwan Habiba, Giuseppe Benagiano","doi":"10.1080/17512433.2025.2517748","DOIUrl":"10.1080/17512433.2025.2517748","url":null,"abstract":"Introduction: Marketing in the late 1950s of Combined Oral Contraceptives (COC) represented the achievement of centuries of research in reproductive endocrinology that included the isolation of the main steroids produced, within the concept of 'internal secretion,' by the ovaries and corpus luteum.Areas covered: Key observations made at the end of the 19th century proved that the presence of corpus luteum induces temporary infertility in animals and that ovaries secrete hormonally active substances. During the 1930s, the four main hormones (progesterone, estrone, estradiol, and estriol) were identified and their structure determined. The recognition that natural compounds are not effective when given orally, stimulated the search for synthetic steroids. Ethinyl-estradiol, synthesized in 1937, remains even today the most widely used estrogenic component of COC, although other compounds (micronized estradiol, estradiol valerate, estetrol) have been incorporated in COC. A variety of synthetic progestins have become available since the early 1950s having different progestogenic potency, pharmacokinetic and pharmacodynamic properties.Expert opinion: Started with observations made three centuries ago, development of COC has gone beyond the dream of the early investigators: literally dozens of formulations are available today capable of satisfying the needs of the majority of women of fertile age and the work continues.","PeriodicalId":12207,"journal":{"name":"Expert Review of Clinical Pharmacology","volume":" ","pages":"347-360"},"PeriodicalIF":3.6,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144257692","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Early response is a strong predictor of the long-term response in psoriasis patients receiving risankizumab or guselkumab in the real-world: a retrospective analysis. 早期反应是现实世界中接受瑞沙单抗或guselkumab治疗的牛皮癣患者长期反应的一个强有力的预测因素：回顾性分析。

IF 3.6 3区医学

Expert Review of Clinical Pharmacology Pub Date : 2025-06-01 Epub Date: 2025-07-02 DOI: 10.1080/17512433.2025.2527098

Neslihan Akdogan, Ömer Kutay Mutlu, Erdem Karabulut, Basak Yalici-Armagan, Duygu Gulseren, Sibel Dogan Gunaydın

{"title":"Early response is a strong predictor of the long-term response in psoriasis patients receiving risankizumab or guselkumab in the real-world: a retrospective analysis.","authors":"Neslihan Akdogan, Ömer Kutay Mutlu, Erdem Karabulut, Basak Yalici-Armagan, Duygu Gulseren, Sibel Dogan Gunaydın","doi":"10.1080/17512433.2025.2527098","DOIUrl":"10.1080/17512433.2025.2527098","url":null,"abstract":"Background: Recognizing early treatment indicators that forecast the long-term effectiveness of maintenance therapy in psoriasis (PsO) could support the optimization of personalized treatments. We aimed to evaluate whether an early response can predict long-term outcomes in patients receiving risankizumab or guselkumab, and to explore the factors associated with responses.Research design and methods: This retrospective study included PsO patients who received risankizumab or guselkumab continuously at least 1 year. The study measured disease severity using the Psoriasis Area Severity Index (PASI) and determined the percentage of patients treated with risankizumab or guselkumab who showed PASI50 at the 3rd month (early response), and assessed whether early response was associated with maintaining long-term response (PASI75 response at the 1st year).Results: A total of 102 patients, including 60 who received risankizumab and 42 who received guselkumab, were enrolled. Early response at the 3rd month strongly predicted treatment outcomes at 12 months. Among early responders, the likelihood of achieving a long-term response was found to be 94.9%.Conclusions: In patients with PsO treated with risankizumab or guselkumab, early response was a significant factor in maintaining stable long-term response. Therefore, early response is a clinically relevant factor to consider when optimizing individual therapeutic strategies.","PeriodicalId":12207,"journal":{"name":"Expert Review of Clinical Pharmacology","volume":" ","pages":"417-423"},"PeriodicalIF":3.6,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144511756","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Practical challenges and considerations in adopting biosimilars in oncology clinical practice within a large healthcare system. 实际的挑战和考虑采用生物仿制药在肿瘤临床实践中的大型医疗保健系统。

IF 3.6 3区医学

Expert Review of Clinical Pharmacology Pub Date : 2025-06-01 Epub Date: 2025-04-30 DOI: 10.1080/17512433.2025.2492063

Mansoor A Khan, Laila Carolina Abu Esba, Consuela Cheriece Yousef, Mohammed Alharbi, Hind Modaimegh, Hend Metwali, Hana Abdulkarim, Majed Alshamrani, Mohamad Aseeri, Mubarak Almansour, Ahmad Alsaeed, Mousa Alahmari, Anjum Naeem Ansari, Meteb Alfoheidi, Ahmed Absi, Turki Alfayea, Eman Youssif, Ayman Alhejazi, Mansour Alodhaib

{"title":"Practical challenges and considerations in adopting biosimilars in oncology clinical practice within a large healthcare system.","authors":"Mansoor A Khan, Laila Carolina Abu Esba, Consuela Cheriece Yousef, Mohammed Alharbi, Hind Modaimegh, Hend Metwali, Hana Abdulkarim, Majed Alshamrani, Mohamad Aseeri, Mubarak Almansour, Ahmad Alsaeed, Mousa Alahmari, Anjum Naeem Ansari, Meteb Alfoheidi, Ahmed Absi, Turki Alfayea, Eman Youssif, Ayman Alhejazi, Mansour Alodhaib","doi":"10.1080/17512433.2025.2492063","DOIUrl":"10.1080/17512433.2025.2492063","url":null,"abstract":"Introduction: Biosimilars have the potential to offer cost savings with comparable efficacy and safety to innovator products and, thus, increase access to treatment for more patients. However, there were significant challenges in the acceptance of oncology biosimilars in our organization in the beginning which we addressed by implementing practical strategies described in the paper.Areas covered: While much of the published literature places an emphasis on the pharmacoeconomic impact of biosimilars, this paper is a novel addition to the literature because it provides practical experience and detailed processes for the formulary adoption and implementation of oncology biosimilars along with a focus on their pharmacoeconomic impact, education of oncology healthcare professionals, pharmacovigilance, and integration into the electronic health record. A narrative literature review was conducted to identify the existing evidence on biosimilar adoption and implementation in the oncology setting.Expert opinion: Healthcare organizations must establish a consistent method for assessing and adopting oncology biosimilars to increase efficiency and coordination among the many team members responsible for their introduction into clinical practice. Conducting medication use evaluations and real-world evidence studies of biosimilars can help in building trust among healthcare professionals and patients in biosimilars.","PeriodicalId":12207,"journal":{"name":"Expert Review of Clinical Pharmacology","volume":" ","pages":"323-331"},"PeriodicalIF":3.6,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143999678","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Management of polypharmacy through deprescribing in older patients: a review of the role of AI tools. 通过老年患者的处方管理多药：人工智能工具的作用综述。

IF 3.6 3区医学

Expert Review of Clinical Pharmacology Pub Date : 2025-06-01 Epub Date: 2025-06-13 DOI: 10.1080/17512433.2025.2519648

Ahmad Z Al Meslamani

{"title":"Management of polypharmacy through deprescribing in older patients: a review of the role of AI tools.","authors":"Ahmad Z Al Meslamani","doi":"10.1080/17512433.2025.2519648","DOIUrl":"10.1080/17512433.2025.2519648","url":null,"abstract":"Introduction: Deprescribing is crucial for improving patient safety since polypharmacy in older adults raises the likelihood of negative health outcomes. Artificial intelligence (AI) role in deprescribing has been rarely addressed.Areas covered: This review looks at how AI techniques are now affecting evidence-based deprescribing for older patients. Studies addressing AI applications, including chatbots, mobile apps, clinical decision support systems (CDSS), and machine learning (ML) algorithms, were found through a thorough literature search. Using a broad range of AI, deprescribing, and older adult-related keywords, relevant studies published up until November 2024 were found through thorough searches of electronic databases. This review finds that these technologies help physicians forecast adverse drug events, identify potentially inappropriate drugs, and enhance medication management.Expert opinion: AI-powered solutions have potential to improve patient outcomes and deprescribing procedures. However, issues including data quality, clinical acceptability, technology integration, and ethical considerations make practical adoption difficult. Extensive validation studies are required to confirm the safety and efficacy of these instruments. To make sure they enhance rather than complicate the deprescribing process, careful integration and ongoing assessment are necessary. Although AI can facilitate tailored deprescribing practice, it is essential to maintain human clinical touch and the patient-clinician interaction.","PeriodicalId":12207,"journal":{"name":"Expert Review of Clinical Pharmacology","volume":" ","pages":"333-345"},"PeriodicalIF":3.6,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144274546","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0